Q4 2021 BioArctic AB Earnings Call Transcript
Hello, and welcome to the BioArctic Audiocast for Teleconference Q4 2021. (Operator Instructions) Just to remind you, this conference call is being recorded.
Today, I am pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please go ahead with your meeting.
()-
Thank you, and good morning, and welcome to BioArctic's full year report for 2021. I will also give some highlights from the fourth quarter. I'm Gunilla Osswald, and I'm the CEO of BioArtic, and I will share today's presentation with our CFO, Jan Mattsson.
It has been a great year for BioArctic and lecanemab, and it is time of hope for Alzheimer's patients. Lecanemab got fast track and breakthrough therapy designation by the FDA during the last year. And our partner Eisai has had interactions with the FDA. And after that, they have initiated a rolling submission, which is ongoing for an accelerated approval for lecanemab in the U.S.
I think that this year will be the most exciting year for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |